SCHEMBL24076896

SCHEMBL24076896

CC(C)c1n[nH]c(=O)c2ccc(C(F)(F)F)cc12

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.44
▸ PARP1 P09874 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ POLB P06746 1/20 0.41
▸ PRMT5 O14744 1/20 0.40
▸ WDR77 Q9BQA1 1/20 0.40
▸ AURKB Q96GD4 1/20 0.40
▸ PDE2A O00408 3/20 0.39
▸ NLRP3 Q96P20 2/20 0.39
▸ NOTUM Q6P988 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ JUN P05412 1/20 0.38
▸ NFKB1 P19838 1/20 0.38
▸ NFKB2 Q00653 1/20 0.38
▸ RELA Q04206 1/20 0.38
▸ TSHR P16473 1/20 0.37
▸ GSK3B P49841 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29426569 1.00 MAPT (0.44) MAPTPARP1SMN1; SMN2POLBPRMT5
SCHEMBL29426515 0.94 PARP1 (0.42) MAPTPARP1SMN1; SMN2POLBPRMT5
SCHEMBL26732910 0.94 PARP1 (0.42) MAPTPARP1SMN1; SMN2POLBPRMT5
SCHEMBL24076281 0.89 POLB (0.40) MAPTSMN1; SMN2POLBPRMT5WDR77
SCHEMBL30451535 0.87 MAPT (0.45) MAPTPARP1SMN1; SMN2PRMT5WDR77
SCHEMBL26732593 0.87 MAPT (0.45) MAPTPARP1SMN1; SMN2PRMT5WDR77
SCHEMBL24076279 0.87 POLB (0.42) MAPTSMN1; SMN2POLBPRMT5WDR77
SCHEMBL24076885 0.84 POLB (0.43) MAPTPARP1SMN1; SMN2POLBPRMT5
SCHEMBL15723643 0.80 MAP2K4 (0.52) GSK3B
SCHEMBL16675888 0.80 TRPA1 (0.51) MAPTHSD17B10GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230357162-A1 COMPOUNDS, COMPOSITIONS AND METHODS TENVIE THERAPEUTICS, INC. 2023-11-09 — — US disclosed
US-20230202989-A1 COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2023-06-29 — — US disclosed
US-20230202989-A1 COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2023-06-29 — — US disclosed
CN-116261456-A Compounds, compositions, and methods 戴纳立制药公司 2023-06-13 — — CN disclosed
WO-2021239885-A1 COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2021-12-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230202989-A1 COMPOUNDS NLRP3, NLRP1, IL1B MAPT 1004/4885PARP1 403/4885SMN1; SMN2 4739/4885
US-20230357162-A1 COMPOUNDS, COMPOSITIONS AND METHODS NLRP3, NLRP1, NOD1 MAPT 3736/4885PARP1 1511/4885SMN1; SMN2 4102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback